Raymond James Financial Services Advisors Inc. Buys 5,261 Shares of Johnson & Johnson (NYSE:JNJ)

Raymond James Financial Services Advisors Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,222,498 shares of the company’s stock after purchasing an additional 5,261 shares during the quarter. Johnson & Johnson comprises 0.7% of Raymond James Financial Services Advisors Inc.’s holdings, making the stock its 16th largest holding. Raymond James Financial Services Advisors Inc. owned 0.08% of Johnson & Johnson worth $380,234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of JNJ. BlackRock Inc. raised its stake in Johnson & Johnson by 1.9% in the third quarter. BlackRock Inc. now owns 195,038,467 shares of the company’s stock valued at $31,498,715,000 after buying an additional 3,653,357 shares during the last quarter. Geode Capital Management LLC raised its stake in Johnson & Johnson by 2.6% in the third quarter. Geode Capital Management LLC now owns 43,320,776 shares of the company’s stock valued at $6,977,300,000 after buying an additional 1,106,544 shares during the last quarter. Morgan Stanley raised its stake in Johnson & Johnson by 3.1% in the second quarter. Morgan Stanley now owns 25,066,744 shares of the company’s stock valued at $4,129,496,000 after buying an additional 760,796 shares during the last quarter. Franklin Resources Inc. raised its stake in Johnson & Johnson by 1.7% in the third quarter. Franklin Resources Inc. now owns 16,392,226 shares of the company’s stock valued at $2,647,348,000 after buying an additional 273,957 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Johnson & Johnson by 11.4% in the third quarter. Invesco Ltd. now owns 11,513,874 shares of the company’s stock valued at $1,859,489,000 after buying an additional 1,178,956 shares during the last quarter. 67.84% of the stock is currently owned by institutional investors.

JNJ stock traded down $3.00 during trading on Friday, hitting $180.46. 8,464,103 shares of the company traded hands, compared to its average volume of 7,853,935. The stock’s 50-day simple moving average is $175.43 and its 200 day simple moving average is $169.36. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.35 and a quick ratio of 1.12. The company has a market cap of $474.48 billion, a PE ratio of 24.32, a P/E/G ratio of 3.01 and a beta of 0.72. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, beating the consensus estimate of $2.61 by $0.06. Johnson & Johnson had a return on equity of 37.03% and a net margin of 20.90%. The company had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. During the same period last year, the business earned $2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.0% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.2 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be issued a $1.13 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.50%. The ex-dividend date of this dividend is Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.14%.

A number of equities research analysts have commented on the company. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and increased their price target for the company from $180.00 to $183.00 in a research note on Wednesday, March 16th. Citigroup raised their price objective on Johnson & Johnson from $203.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, April 20th. Morgan Stanley reduced their price objective on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. Bank of America assumed coverage on Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating for the company. Finally, The Goldman Sachs Group raised their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Buy” and an average target price of $188.57.

In other news, insider William Hait sold 29,699 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total value of $4,173,776.25. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories